4//SEC Filing
Schmidt Joan 4
Accession 0001209191-21-024878
CIK 0001080709other
Filed
Apr 1, 8:00 PM ET
Accepted
Apr 2, 8:10 PM ET
Size
9.9 KB
Accession
0001209191-21-024878
Insider Transaction Report
Form 4
Schmidt Joan
EVP, General Counsel & Sec
Transactions
- Exercise/Conversion
Common Stock
2021-03-15+12,600→ 19,475 total - Exercise/Conversion
Performance Restricted Stock Unit
2021-03-15−12,600→ 0 totalExp: 2022-01-03→ Common Stock (12,600 underlying) - Tax Payment
Common Stock
2021-03-15$77.58/sh−4,874$378,125→ 14,601 total
Footnotes (3)
- [F1]On March 15, 2020, the Reporting Person was granted 6,300 target Performance Restricted Stock Units ("2020 PRSUs"). The 2020 PRSUs represented a contingent right to receive a number of shares of Arena's common stock equal to 0%, 100%, or 200% of the target amount. Such common shares would vest, if at all, upon Arena's common stock reaching certain Nasdaq "Closing Price" thresholds during the performance period from the grant date through Jan. 3, 2022 (the "Performance Period") and satisfaction of a subsequent continuing service requirement. The 2020 PRSUs also contained a 1-year minimum vesting period. The Closing Price targets were met during 2020 and the continuing service requirements were subsequently satisfied. Therefore, upon the conclusion of the 1-year minimum vesting period, all shares shares issuable pursuant to the 2020 PRSUs (200% of the target amount) vested and released as reported herein.
- [F2]Represents the number of shares withheld by, and surrendered to, Arena relating to tax withholding in connection with the issuance of shares under the 2020 PRSUs.
- [F3]The amount reported in Column 7 of Table II represents the common shares that vested. The 2020 PRSUs have now fully vested and no common shares remain issuable thereunder.
Documents
Issuer
ARENA PHARMACEUTICALS INC
CIK 0001080709
Entity typeother
Related Parties
1- filerCIK 0001805334
Filing Metadata
- Form type
- 4
- Filed
- Apr 1, 8:00 PM ET
- Accepted
- Apr 2, 8:10 PM ET
- Size
- 9.9 KB